Rhythm Pharmaceuticals, Inc. (RYTM) 2026 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals second-quarter 2026 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.

    各位早安,感謝您稍候。歡迎參加 Rhythm Pharmaceuticals 2026 年第二季財報電話會議。(接線員指示) 請注意,今天的會議將被錄音。

  • I would now like to hand the conference over to your first speaker today, David Connolly, Investor Relations at Rhythm Pharmaceuticals. Please go ahead.

    現在我想把會議交給今天的第一位講者,Rhythm Pharmaceuticals 投資人關係部的 David Connolly。請開始。

  • David Connolly - Head of Investor Relations and Corporate Communications

    David Connolly - Head of Investor Relations and Corporate Communications

  • Thank you, Didi. I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the Investors section of our website, ir.rhythmtx.com. This morning, we issued our press release that provides our Q2 2026 financial results and a business update, and that press release is available on our website. We also released data for RM-718's Phase 2 trial in acquired hypothalamic obesity.

    謝謝你,Didi。我是 Rhythm Pharmaceuticals 的 Dave Connolly。各位參與電話會議的朋友,我們的簡報可透過造訪我們網站 ir.rhythmtx.com 的「投資人」專區進行存取與控制。今天早上,我們發布了新聞稿,提供 2026 年第二季財務結果與業務更新;該新聞稿可在我們網站上取得。我們也公布了 RM-718 在後天性下視丘性肥胖(acquired hypothalamic obesity)第二期試驗的數據。

  • Our agenda today is listed on slide two. On the call are David Meeker, our Chairman, Chief Executive Officer and President; Jennifer Lee, Executive Vice President, Head of North America; Hunter Smith, Chief Financial Officer; and Yann Mazabraud, Executive Vice President, Head of International, is on the line joining us from Europe.

    今天的議程列於投影片二。出席本次電話會議的有:董事長、執行長兼總裁 David Meeker;北美區負責人、執行副總裁 Jennifer Lee;財務長 Hunter Smith;以及國際事業負責人、執行副總裁 Yann Mazabraud,他將從歐洲連線加入。

  • On slide three, I'll remind you this call contains remarks concerning future expectations, plans and prospects, which constitutes forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual or quarterly reports on file with the SEC.

    在投影片三,我提醒各位,本次電話會議包含對未來預期、計畫與展望的評論,構成前瞻性陳述。由於多項重要因素,實際結果可能與這些前瞻性陳述所示有重大差異,包括我們最近提交給美國證券交易委員會(SEC)的年度或季度報告中所討論的因素。

  • In addition, any forward-looking statements represent our views as of today, and should not be relied upon as representing our views as of any subsequent dates. We specifically disclaim any obligation to update such statements.

    此外,任何前瞻性陳述僅代表我們截至今日的觀點,不應被依賴為代表我們在任何後續日期的觀點。我們明確聲明不負有更新此類陳述的任何義務。

  • With that, I'll turn the call over to David Meeker, who will begin on slide five.

    接下來,我把電話交給 David Meeker,他將從投影片五開始。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • Good morning, and thank you for joining us. We have a lot to share today, headlined by a strong start to the US launch of IMCIVREE for acquired hypothalamic obesity, reinforcing our conviction that HO represents a meaningful long-term opportunity for Rhythm.

    各位早安,感謝加入我們。今天我們有許多內容要分享,重點是 IMCIVREE 在美國針對後天性下視丘性肥胖(HO)的上市開局強勁,進一步強化我們的信念:HO 對 Rhythm 而言代表一個具意義的長期機會。

  • Progress during the quarter wasn't limited to our commercial business. In June, we presented positive six-month data in Prader-Willi at ENDO, showing setmelanotide achieved clinically meaningful BMI and BMI z-score reductions in fat mass and preservation of lean mass, and improvements in hyperphagia and anxiety measures. These data confirm the mechanistic rationale that MC4 agonism plays a key role in the pathology of PWS and demonstrated the positive impact IMCIVREE can have in this difficult-to-treat patient population.

    本季的進展不僅限於商業業務。6 月,我們在 ENDO 會議上發表了 Prader-Willi 症候群的正向六個月數據,顯示 setmelanotide 在脂肪量下降與瘦體重維持方面,達到具臨床意義的 BMI 與 BMI z 分數降低,並改善暴食(hyperphagia)與焦慮指標。這些數據確認了 MC4 受體致效作用(MC4 agonism)在 PWS 病理機轉中扮演關鍵角色的機制性理據,並展示 IMCIVREE 能在這個難以治療的病人族群中帶來正向影響。

  • We look forward to updating you on a path forward for PWS in the next few months, which brings us to our pipeline. We believe our next-generation MC4R agonists have the potential to bring meaningful new treatment options to patients living with rare neuroendocrine diseases.

    我們期待在未來幾個月向各位更新 PWS 的後續推進路徑,這也帶到我們的研發管線。我們相信,我們的次世代 MC4R 致效劑有潛力為罹患罕見神經內分泌疾病的病人帶來具意義的新治療選擇。

  • And today, we announced encouraging results to demonstrate RM-718, our weekly MC4R agonist, has the potential to deliver clinically meaningful BMI reductions in patients with acquired hypothalamic obesity with efficacy comparable to what we've demonstrated with setmelanotide and bivamelagon, and importantly, a favorable tolerability profile with no reports of generalized hyperpigmentation.

    此外今天,我們公布了令人鼓舞的結果,顯示 RM-718(我們的每週一次 MC4R 致效劑)在後天性下視丘性肥胖病人中,有潛力帶來具臨床意義的 BMI 降幅,其療效可與我們在 setmelanotide 與 bivamelagon 上所展示的結果相當;更重要的是,其耐受性表現良好,且未出現全身性皮膚色素沉著(generalized hyperpigmentation)的通報。

  • But first, let me comment on the IMCIVREE launch in HO. This is a unique, severe, rare disease marked by accelerated and sustained weight gain caused by a brain tumor and/or its treatment, or other brain injury to the hypothalamus that impairs the MC4R pathway.

    不過首先,讓我先評論 IMCIVREE 在 HO 的上市進展。這是一種獨特、嚴重且罕見的疾病,其特徵為因腦腫瘤及/或其治療,或其他造成下視丘損傷的腦部傷害而導致體重加速且持續增加,並使 MC4R 路徑受損。

  • Acquired HO is clearly distinct from general obesity and remains underdiagnosed and underrecognized. With an estimated 10,000 patients in the US, a similar number in Europe, and between 5,000 and 8,000 patients in Japan, this represents a significant global opportunity. In July, results from the Phase 3 HO TRANSCEND trial were published in the New England Journal of Medicine by lead author Dr. Jennifer Miller and senior author Dr. Christian Roth, two of the world's leading experts in HO.

    後天性 HO 顯然不同於一般肥胖,且仍存在診斷不足與認知不足的情況。美國估計約有 10,000 名病人,歐洲數量相近,日本則約 5,000 至 8,000 名病人,這代表顯著的全球機會。7 月,第三期 HO TRANSCEND 試驗結果由第一作者 Jennifer Miller 醫師與資深作者 Christian Roth 醫師(兩位皆為全球 HO 領域的頂尖專家)發表於《新英格蘭醫學期刊》(New England Journal of Medicine)。

  • In addition, as shown on slide six, the New England Journal of Medicine published an accompanying editorial with its Science Behind the Study feature, authored by Professor Sadaf Farooqi, one of the world's leading experts in the MC4R pathway diseases.

    此外,如投影片六所示,《新英格蘭醫學期刊》亦刊登了隨附社論及其「研究背後的科學」(Science Behind the Study)專欄文章,由 Sadaf Farooqi 教授撰寫;她是全球 MC4R 路徑疾病領域的頂尖專家之一。

  • Articles like this in the New England Journal of Medicine, 10 years after the Palm State Efficiency New England Journal of Medicine article that put Rhythm on the map, raised visibility of a historically under-recognized disease among clinicians, researchers, and payers, and further establishes setmelanotide as a clinically meaningful advancement for patients. The awareness that there is an effective therapy for a rare disease increases the urgency on all parts of the healthcare system. Getting to a diagnosis matters when there's a precision medicine available.

    像這樣刊登於《新英格蘭醫學期刊》的文章——距離 10 年前那篇讓 Rhythm 受到關注的《新英格蘭醫學期刊》文章之後——提升了臨床醫師、研究人員與支付方對一項歷來較少被認識之疾病的能見度,並進一步確立 setmelanotide 對病人而言是一項具臨床意義的進展。當罕見疾病存在有效療法時,整個醫療體系各環節的急迫性都會提高。當有精準醫療可用時,能否做出診斷就至關重要。

  • The New England Journal of Medicine article follows on the heels of the FDA approval on March 19 of this year. Throughout 2025 and 2026, our teams have been in the field focused on disease awareness and patient identification, engaging endocrinologists to deepen understanding of acquired HO, and the connection between hypothalamic injury and the disruption of the MC4R pathway.

    這篇《新英格蘭醫學期刊》文章緊接在今年 3 月 19 日 FDA 核准之後。在 2025 與 2026 年期間,我們的團隊持續在第一線推動疾病認知與病人辨識,與內分泌科醫師互動,以加深對後天性 HO 的理解,以及下視丘損傷與 MC4R 路徑失調之間的關聯。

  • Our HO launch builds on this engagement and the successful commercial effort in BBS, an opportunity that continues to grow. Rhythm now has a mature, rare disease commercial platform built on four years of commercial success and established relationships across physicians, payers, and patient communities.

    我們的 HO 上市建立在上述互動基礎之上,也延續了我們在 BBS 的成功商業化成果;該機會仍在持續成長。Rhythm 現已擁有成熟的罕見疾病商業平台,建立於四年的商業成功,以及在醫師、支付方與病友社群之間所建立的既有關係。

  • We're off to a promising start with this next phase of growth. With strong demand from patients and families, a broad and growing prescriber base, and a positive reception from payers, we are encouraged with the first 14 weeks of the US launch. Since approval on March 19, we have received more than 400 start forms from approximately 300 prescribers.

    在這個下一階段的成長上,我們已取得令人振奮的開局。在病人與家庭的強勁需求、廣泛且持續擴大的處方醫師基礎,以及支付方的正向回饋下,我們對美國上市前 14 週的表現感到鼓舞。自 3 月 19 日核准以來,我們已從約 300 位處方醫師收到超過 400 份啟動表單(start forms)。

  • Jennifer will provide additional color on the US launch. Yann will detail the next steps toward anticipated approval and launch in Japan this year, and country-level launches in Europe next year.

    Jennifer 將就美國上市提供更多細節。Yann 將說明今年在日本預期核准與上市的下一步,以及明年在歐洲各國分別上市的規劃。

  • We are mindful that it is early days. However, the first launch quarter performance reinforces our conviction that HO represents a long-term durable and sustainable opportunity for Rhythm.

    我們也清楚目前仍屬早期階段。然而,首個上市季度的表現進一步強化我們的信念:HO 對 Rhythm 而言是一個長期、具韌性且可持續的機會。

  • Now, I want to briefly review preliminary data from the open-label Phase 2 Part C trial of RM-718, our weekly MC4R agonist and acquired HO. RM-718 is one of two next-generation MC4R agonists that have the potential to improve on the hyperpigmentation and convenience of setmelanotide. The weight loss efficacy for each of these three assets has been remarkably consistent. We believe these preliminary results are encouraging and meaningfully de-risk 718 as a development candidate going forward.

    接下來,我想簡要回顧 RM-718(我們每週一次的 MC4R 致效劑)在後天性 HO 的開放標籤第二期 C 部分試驗之初步數據。RM-718 是兩個次世代 MC4R 致效劑之一,具備在色素沉著與使用便利性方面優於 setmelanotide 的潛力。這三項資產在減重療效方面的表現高度一致。我們認為這些初步結果令人鼓舞,並在未來推進開發候選藥物的過程中,對 718 具有實質的去風險效果。

  • Beginning on slide eight, we show the patient disposition and patient demographics. 11 patients were enrolled and eight patients remain on active therapy. Seven patients have reached 16 weeks and that is the data we are sharing here. Two patients discontinued because of AE during the first four weeks of treatment. One patient stopped because of injection site reactions and a second patient discontinued secondary to ongoing nausea, which could not be controlled even with dose reductions. A third patient completed the 16-week trial period and later withdrew from the long-term extension for personal reasons. Two additional patients have yet to reach the 16-week time point.

    從投影片八開始,我們展示病人處置情況與病人人口統計特徵。共有 11 位病人入組,其中 8 位仍在接受持續治療。已有 7 位病人達到 16 週,這就是我們在此分享的數據。有 2 位病人在治療前四週因不良事件(AE)而中止。其中 1 位因注射部位反應而停止,另 1 位則因持續噁心而中止,即使降低劑量仍無法控制。第 3 位病人完成 16 週試驗期後,因個人因素於長期延伸試驗中退出。另有 2 位病人尚未達到 16 週時間點。

  • Patients in the trial were 12 years of age or older, with a mean BMI of 40.1 per protocol, doses were escalated to 40 miligrams as tolerated. The mean BMI change of 11.6% for the seven patients who have reached week 16 is shown on slide nine.

    試驗中的患者年齡為12歲或以上,依方案其平均BMI為40.1;在可耐受的情況下,劑量逐步遞增至40毫克。已達到第16週的7名患者,其平均BMI變化為下降11.6%,如第九張投影片所示。

  • As you can see on slide 10, these results compare favorably with setmelanotide and bivamelagon results at a similar time point in patients with required HO. In a pooled analysis of patients with the HO and the Phase 2 and Phase 3 setmelanotide trials, the week 16 BMI reduction was 10.1%. For bivamelagon, at 600-milligram dose, mean BMI reduction for seven patients at week 14 was 10.1%.

    如第10張投影片所示,這些結果在相近時間點、針對符合條件之HO患者,與setmelanotide及bivamelagon的結果相比表現良好。在一項彙總分析中,納入HO患者以及第2期與第3期setmelanotide試驗,於第16週的BMI降幅為10.1%。就bivamelagon而言,在600毫克劑量下,7名患者於第14週的平均BMI降幅為10.1%。

  • And slide 11 shows a continued -- with 10.1% and then slide 11 shows a continued deepening of the effect in four patients with 28 weeks or more of treatment.

    而第11張投影片顯示持續——先是10.1%,接著第11張投影片顯示在4名治療達28週或以上的患者中,效果持續加深。

  • As shown on slide 12, RM-718 was generally well tolerated, with most common adverse events being injection site reactions and nausea. Importantly, we have observed no generalized hyperpigmentation with either bivamelagon or 718, which you would expect to see with MC1R agonism.

    如第12張投影片所示,RM-718整體耐受性良好,最常見的不良事件為注射部位反應與噁心。重要的是,我們在bivamelagon或718上均未觀察到全身性皮膚色素沉著增加;若出現MC1R致效作用,通常會預期看到此現象。

  • Overall, these results validate our conviction that 718 has the potential to be a viable treatment option for rare MC4R pathway diseases. Both 718 and bivamelagon have been shown to affect BMI reductions comparable to setmelanotide in patients with acquired HO, and both have greater specificity for the MC4R receptor without generalized hyperpigmentation.

    整體而言,這些結果驗證了我們的信念:718有潛力成為罕見MC4R途徑疾病的可行治療選項。在後天性HO患者中,718與bivamelagon均顯示出與setmelanotide相當的BMI降低效果,且兩者對MC4R受體具有更高特異性,並未出現全身性皮膚色素沉著增加。

  • Importantly, the patent protection for both 718 and biva goes past 2040. We believe today's data further de-risks our ability to build a durable franchise of MC4R agonists.

    重要的是,718與biva的專利保護均延續至2040年以後。我們相信今日的數據進一步降低了我們建立具持久性的MC4R致效劑產品組合(franchise)的風險。

  • Enrollment of PWS patients in Part D of this open-label trial will complete by the end of the year with a goal enrolling 10 to 15 patients. As I mentioned, we are moving closer to a decision on a potential path forward for PWS with setmelanotide, Bivamelagon, or 718, all viable options.

    此開放標籤試驗D部分的PWS患者招募將於年底前完成,目標招募10至15名患者。如我先前所提,我們正更接近就PWS的潛在後續路徑作出決策:setmelanotide、bivamelagon或718皆為可行選項。

  • As a reminder, we are aiming to initiate the Phase 3 trial of bivamelagon and acquired HO at the end of this year, which is listed among the upcoming milestones from slide 13. The first patient's role will be patients 12 and older, as we finalize CMC work for the oral dissolvable tablets in the first quarter of next year.

    提醒一下,我們目標在今年年底啟動bivamelagon用於後天性HO的第3期試驗,這也列在第13張投影片的近期里程碑之中。首位患者的入組將涵蓋12歲及以上患者;同時,我們將於明年第一季完成口溶錠的CMC相關工作。

  • With that, I'll turn the call over to Jennifer and then Yann to provide more color on our strong commercial progress during the quarter.

    接下來,我將把電話會議交給Jennifer,之後再由Yann補充說明本季強勁的商業進展。

  • Jennifer Lee - Executive Vice President, Head of North America

    Jennifer Lee - Executive Vice President, Head of North America

  • Thank you, David. I'll begin on slide 15. I'm pleased to provide an update on the US launch of IMCIVREE for acquired hypothalamic obesity. This was the first full quarter of launch, plus one additional week following FDA approval on March 19. While we remain very early in the launch, we have seen strong demand, broad and expanding prescriber engagement and activation, and positive early payer experience supporting access. Overall, the early indicators are encouraging and reinforce our conviction in the long-term opportunity for acquired hypothalamic obesity.

    謝謝你,David。我將從第15張投影片開始。我很高興就IMCIVREE在美國針對後天性下視丘性肥胖的上市進展提供最新資訊。這是上市後的第一個完整季度,並包含FDA於3月19日核准後額外的一週。雖然我們仍處於上市初期,但已看到強勁需求、處方醫師的廣泛且持續擴大的參與與啟動,以及支持可近性的正面早期支付方(payer)經驗。整體而言,早期指標令人鼓舞,並強化我們對後天性下視丘性肥胖長期機會的信心。

  • On slide 16, I'll start with the patient level metrics. In the 14 weeks between FDA approval on March 19 and June 30, we received more than 400 start forms for acquired hypothalamic obesity. This includes 66 start forms for converted trial patients, accounting for almost all the US trial patients. The age distribution for these patients is evenly split between patients 21 and younger, and those 22 and older, with 21% of prescriptions for patients ages 4 to 11, 18% for patients 12 to 17, and 12% for patients 18 to 21. Care for acquired HO patients tends to be more coordinated in the pediatric setting, and this contributes towards higher rates of recognition and diagnosis.

    在第16張投影片,我先從患者層級指標談起。在FDA於3月19日核准至6月30日的14週期間,我們收到超過400份針對後天性下視丘性肥胖的起始表單(start forms)。其中包含66份由試驗患者轉換而來的起始表單,幾乎涵蓋所有美國試驗患者。這些患者的年齡分布在21歲及以下與22歲及以上之間大致各半;處方中,21%為4至11歲患者、18%為12至17歲患者、12%為18至21歲患者。後天性HO患者的照護在兒科環境中往往更具協調性,這也有助於提高辨識與診斷率。

  • As a result, pediatric patients make up a larger share of our early and (inaudible) rate patients. We expect this to evolve over time and to have a higher contribution for adults in the future. Among these early prescriptions, we see a broad mix of both incident and prevalent patients. Based off an internal analysis of a portion of prescriptions received, approximately 15% of patients suffered the injury resulting in their acquired HO within the last two years.

    因此,兒科患者在我們早期與(聽不清)率患者中占比較高。我們預期這將隨時間推移而演變,未來成人的貢獻度將更高。在這些早期處方中,我們看到新發(incident)與既有(prevalent)患者皆有廣泛分布。根據我們對部分已收到處方的內部分析,約15%的患者是在過去兩年內發生導致其後天性HO的傷害。

  • The majority of stock firms are from prevalent patients living with HO for more than two years, with approximately 50% of patients having their injury occur more than 10 years ago. These early dynamics are encouraging and demonstrate meaningful demand across a broad range of patients.

    大多數起始表單來自既有患者,亦即罹患HO超過兩年的患者;其中約50%的患者其傷害發生於10年以上前。這些早期動態令人鼓舞,顯示在廣泛患者族群中存在具意義的需求。

  • On slide 17 are provider level metrics for the acquired HO launch. We are seeing broad activation and engagement of healthcare providers. Between approval and the end of the second quarter, we have approximately 300 unique prescribers for acquired HO. Approximately 20% of these physicians have prescribed IMCIVREE for more than one patient with acquired HO. In line with our view that this is primarily a specialty opportunity, the majority of prescribers are endocrinologists, with adult and pediatric endocrinologists accounting for 43% and 37% of prescribers, respectively.

    第17張投影片為後天性HO上市的醫療提供者層級指標。我們看到醫療照護提供者的廣泛啟動與參與。自核准至第二季末,我們約有300位針對後天性HO的獨立處方醫師。其中約20%的醫師已為不只一位後天性HO患者開立IMCIVREE。符合我們對此為以專科為主之機會的看法,多數處方醫師為內分泌科醫師;成人與兒科內分泌科醫師分別占處方醫師的43%與37%。

  • We are encouraged by the early activation levels of our priority accounts and top prescriber targets. We've made solid progress in penetrating our priority accounts with 65% activated by the end of June, and almost 25% of prescriptions coming from these accounts.

    我們對優先重點客戶(priority accounts)與主要處方目標的早期啟動程度感到鼓舞。截至6月底,我們在滲透優先重點客戶方面取得穩健進展,已有65%完成啟動,且近25%的處方來自這些客戶。

  • Onto slide 18 and our progress with payers. The early payer experience has been positive and supportive of access, a reflection that payers recognize the severity of acquired HO and, similar to BBS, understand the distinction from general obesity and the benefit of IMCIVREE.

    接著看第18張投影片與我們在支付方方面的進展。早期支付方經驗正面且支持可近性,反映支付方認知到後天性HO的嚴重性,並且與BBS類似,理解其與一般肥胖的差異,以及IMCIVREE所帶來的效益。

  • While we still work to gain access for prescriptions received since approval, we are encouraged by the number of initial approvals that came in at the prior authorization stage during this first quarter of launch. Many through payers without a specific acquired HO policy for IMCIVREE yet in place.

    雖然我們仍在努力為核准後收到的處方爭取可近性,但我們對於在上市第一個季度中、於事前授權(prior authorization)階段即獲得的初始核准數量感到鼓舞。其中許多來自尚未針對IMCIVREE建立特定後天性HO給付政策的支付方。

  • By the end of Q2, we secured positive policies for HO, covering approximately 25% of Medicaid-covered lives and 35% of commercial-covered lives. In line with our expectations, we expect additional policies to become established within the three to nine months post-approval or by the end of this year.

    截至第二季末,我們已取得針對HO的正面給付政策,涵蓋約25%的Medicaid承保人群與35%的商業保險承保人群。符合我們的預期,我們預計在核准後3至9個月內,或於今年年底前,將會建立更多政策。

  • The strength and consistency across these early launch metrics give us confidence this opportunity will continue to build over time, reinforcing our long-term conviction in the acquired HO opportunity and our belief that IMCIVREE can become the standard of care for these patients.

    這些早期上市指標所展現的強度與一致性,使我們有信心此機會將隨時間持續擴大,進一步強化我們對後天性HO機會的長期信念,以及我們相信IMCIVREE可成為這些患者的標準治療。

  • Moving to slide 19. While we are encouraged by the progress in the HO launch, we also feel that there remains opportunity for growth in BBS. We recently supported the publication of a new evidence-based, consensus-driven diagnostic algorithm designed to help physicians identify and diagnose patients with BBS earlier in their disease journey. In a population that has historically been very difficult to diagnose, we believe this is an important step towards enabling more BBS patients to get to a timely diagnosis and appropriate care.

    接著看第19張投影片。雖然我們對HO上市進展感到鼓舞,但我們也認為BBS仍有成長空間。我們近期支持發表了一套新的、以證據為基礎且由共識驅動的診斷演算法,旨在協助醫師在疾病歷程更早期辨識並診斷BBS患者。在一個歷來非常難以診斷的人群中,我們相信這是重要的一步,有助於讓更多BBS患者及時獲得診斷與適切照護。

  • Lastly, on slide 20, we are also evolving our North America commercial organization to ensure acquired HO and BBS each receive dedicated focus to maximize their ability to help patients. With the acquired HO launch now underway, we have made a transition to focus our 42 territory managers exclusively on HO.

    最後,在第 20 張投影片上,我們也正在調整北美商業組織,以確保新取得的 HO 與 BBS 各自都能獲得專注資源,以最大化其協助病患的能力。隨著新取得的 HO 上市推進中,我們已完成轉型,將 42 位區域經理的工作重心專注於 HO。

  • We modified our field team structure, so we now have a new territory manager group dedicated to BBS, with plans to grow this to 10 TM. This reflects our long-term commitment to patients living with BBS. These changes allow us to pursue both opportunities with dedicated teams, ensuring focused execution and acquired HO, while continuing to build upon the strong foundation we have established in BBS.

    我們調整了外勤團隊架構,因此目前新增一個專責 BBS 的區域經理團隊,並計畫將其擴編至 10 位 TM。這反映了我們對 BBS 病患的長期承諾。這些變更讓我們能以專責團隊同時推進兩項機會,確保在新取得的 HO 上聚焦執行,同時持續在我們已為 BBS 建立的堅實基礎上再接再厲。

  • Now, let me hand it over to you on.

    現在,讓我把時間交給你,Jon。

  • Yann Mazabraud - Executive Vice President, Head of International

    Yann Mazabraud - Executive Vice President, Head of International

  • Thank you, Jennifer. Our strong international commercial performance continued during the second quarter as the number of patients on IMCIVREE continues to grow, either through national reimbursements or named patient sales. And we have also made significant progress in Europe and Japan toward our goal of bringing IMCIVREE to patients with acquired hypothalamic obesity.

    謝謝你,Jennifer。第二季我們強勁的國際商業表現持續延伸,因為使用 IMCIVREE 的病患人數持續成長,來源包括國家給付(reimbursement)或具名病患銷售(named patient sales)。同時,我們在歐洲與日本也朝著將 IMCIVREE 帶給後天性下視丘性肥胖(acquired hypothalamic obesity)病患的目標取得重大進展。

  • Slide 22. We are entering the final stages in the regulatory process toward approval and launch in Japan. We anticipate IMCIVREE approval for acquired HO and launch in Japan by year-end 2026. Following the PMDA review, we anticipate marketing authorization from the Japan Ministry of Health, Labor and Welfare or MHLW. Once we receive marketing authorization, we would begin pricing discussion with Japan National Health Insurance Authority. And this process can take two to three months. With this timeline, we would anticipate commercial launch in Japan in the fourth quarter.

    第 22 張投影片。我們正進入日本核准與上市之法規流程的最後階段。我們預期 IMCIVREE 針對後天性 HO 將於 2026 年底前在日本獲准並上市。在 PMDA 審查之後,我們預期將取得日本厚生勞動省(MHLW)的上市許可(marketing authorization)。一旦取得上市許可,我們將開始與日本全民健康保險主管機關進行定價討論。此流程可能需要兩到三個月。依此時程,我們預期可於第四季在日本進行商業上市。

  • With approximately 5,000 to 8,000 patients living with acquired hypothalamic obesity in Japan, which is a higher per capita prevalence than the United States or Europe, Japan represents a meaningful opportunity. Our team in Japan is in place, actively engaging with a community of experts, patients and caregivers. Similar to the approach Jennifer's team took in the US, we are engaging with the treatment community to identify potential patients ahead of launch. We will share more details about Japan on our next quarterly conference call.

    日本約有 5,000 至 8,000 名後天性下視丘性肥胖病患,其人均盛行率高於美國或歐洲,因此日本代表一個具意義的機會。我們在日本的團隊已就位,正積極與專家、病患與照護者社群互動。類似 Jennifer 團隊在美國採取的方式,我們正與治療社群合作,在上市前提前辨識潛在病患。我們將在下一次季度電話會議中分享更多關於日本的細節。

  • Next slide, turning to commercialization of IMCIVREE for acquired HO in Europe. In May, the European Commission granted marketing authorization for IMCIVREE for the treatment of obesity and control of hunger in patients four years of age and older with acquired hypothalamic obesity due to hypothalamic injury or impairment.

    下一張投影片,轉到 IMCIVREE 在歐洲針對後天性 HO 的商業化。5 月,歐盟執委會核發 IMCIVREE 的上市許可,用於治療因下視丘損傷或功能受損所致之後天性下視丘性肥胖、並控制飢餓感,適用於 4 歲以上病患。

  • We have a very experienced team in place, working through country-level processes to secure market access and reimbursement, which we have successfully done in the past years for POMC LEPR, BBS, and the pediatric label expansion.

    我們已建立一支經驗非常豐富的團隊,正逐國推進流程以取得市場准入與給付,我們在過去幾年已成功為 POMC、LEPR、BBS,以及兒科適應症擴增完成相同工作。

  • In Germany, we anticipate launching in the first half of 2027. We are encouraged by the initial engagement in the process to secure an exemption from the German Federal Joint Committee or G-BA Annex II exclusion list. The GBA Annex II exclusion list prohibits reimbursement for lifestyle drugs, such as drugs indicated for smoking cessation and general obesity.

    在德國,我們預期於 2027 年上半年上市。我們對於在流程初期所獲得的互動感到鼓舞,目標是取得德國聯邦聯合委員會(G-BA)附件 II 排除清單(Annex II exclusion list)的豁免。G-BA 附件 II 排除清單禁止對生活型態用藥給付,例如戒菸用藥與一般性肥胖適應症用藥。

  • We are confident in our ability to secure an exemption, enabling a reimbursement for acquired HO, as we have done it before for all our previous indications. We are making progress toward market access elsewhere in Europe. We have submitted the dossiers to begin pricing discussions in France, in the UK, in Italy, in Spain, and in the Netherlands with launches in each country anticipated in 2027 following Germany.

    我們對於取得豁免、進而使後天性 HO 可獲給付的能力充滿信心,因為我們先前已在所有既有適應症上成功做到。我們也在歐洲其他地區的市場准入方面持續取得進展。我們已提交檔案(dossiers),以啟動在法國、英國、義大利、西班牙與荷蘭的定價討論;在德國之後,預期各國將於 2027 年陸續上市。

  • With an estimated prevalence of approximately 10,000 patients in Europe, it is a meaningful opportunity and our early access programs in France and in Italy have enabled many of the leading physicians to gain experience with setmelanotide and see the benefit in patients living with HO.

    歐洲估計盛行人數約 10,000 名,這是一個具意義的機會;而我們在法國與義大利的早期用藥計畫(early access programs)已讓許多領先醫師得以累積 setmelanotide 的使用經驗,並看到其對 HO 病患的效益。

  • In May, we presented approximately a dozen posters at the European Congress of Endocrinology and at the European Congress on Obesity. Next month, at the 2026 European Society for Pediatric Endocrinology meeting, we have had three abstracts accepted for oral presentations and three accepted for poster presentations. And there are two additional non-Rhythm-sponsored presentations that will highlight findings in patients living with BBS from Germany and the UK.

    5 月,我們在歐洲內分泌學會年會(European Congress of Endocrinology)以及歐洲肥胖大會(European Congress on Obesity)發表了約一打的海報。下個月在 2026 年歐洲小兒內分泌學會年會(European Society for Pediatric Endocrinology)上,我們有三篇摘要獲選口頭報告、另有三篇獲選海報展示。此外,還有兩場非 Rhythm 贊助的報告,將重點呈現德國與英國 BBS 病患的研究發現。

  • We have approximately 75 abstracts, both originals and encores, submitted and presented and/or slated for presentation this year in European and Japanese medical congresses, giving us an unparalleled level of engagement with the international experts and healthcare providers.

    今年我們在歐洲與日本的醫學會議中,已提交並發表和/或預計發表約 75 篇摘要(包含原創與再呈現),使我們與國際專家及醫療照護提供者的互動達到前所未有的程度。

  • With that, I will turn it over to Hunter.

    接下來,我把時間交給 Hunter。

  • Hunter Smith - Chief Financial Officer, Treasurer

    Hunter Smith - Chief Financial Officer, Treasurer

  • Thank you, Yann. I will begin on slide 25. We exited the second quarter in a solid financial position and are encouraged by our strong initial launch execution and acquired HO in the US. At the same time, we continue to make meaningful progress with BBS in the US and internationally, underscoring the strength of our business and the opportunity we see for continued growth.

    謝謝你,Yann。我將從第 25 張投影片開始。我們在第二季結束時維持穩健的財務狀況,並對於在美國針對後天性 HO 的上市初期執行表現強勁感到振奮。同時,我們在美國及國際市場的 BBS 也持續取得具意義的進展,凸顯我們業務的韌性,以及我們所看到的持續成長機會。

  • We had a strong second quarter of 2026. Global net product sales of IMCIVREE totaled $71.3 million, which represents 19% sequential growth over Q1. During the second quarter, $51 million or 72% of product revenue was generated in the United States.

    2026 年第二季表現強勁。IMCIVREE 全球產品淨銷售額合計 7,130 萬美元,較第一季呈現 19% 的季增。第二季中,美國貢獻 5,100 萬美元,約占產品營收的 72%。

  • Globally, we saw continued growth in patients on reimbursed therapy with an increase of greater than 20% over the prior quarter, primarily driven by the acquired HO launch and continued growth in BBS in the US, as well as ex-US growth in BBS and our HO early access programs.

    在全球範圍內,我們看到接受給付治療(reimbursed therapy)的病患人數持續成長,較前一季增加超過 20%,主要由美國後天性 HO 上市帶動,以及美國 BBS 的持續成長,並包括美國以外地區 BBS 的成長與我們 HO 早期用藥計畫的推進。

  • On slide 26, I'll walk you through the quarter-over-quarter revenue change, with revenue increasing from $60.1 million in Q1 '26 to $71.3 million in Q2. We saw an $11.3 million in revenue growth attributable to increased product demand in the US. A bit more than half of this increase came from the strong start in the US launch for acquired HO, where a percentage of our early scripts converted to starts at the prior [autho] stage, as Jennifer mentioned previously.

    在第 26 張投影片,我將帶各位看季對季營收變動:營收由 2026 年第一季的 6,010 萬美元增加至第二季的 7,130 萬美元。其中有 1,130 萬美元的營收成長可歸因於美國產品需求增加。這項增加中略多於一半來自美國後天性 HO 上市的強勁開局;如 Jennifer 先前提到,我們部分早期處方在先前的 [autho] 階段轉換為開始用藥(starts)。

  • BBS had a strong quarter as well with higher demand growth and strong compliance compared to what we have experienced in other recent quarters. GTN improved somewhat in the quarter to 86%, providing an additional support to Q2 revenue.

    BBS 在本季同樣表現強勁,需求成長更高,且依從性(compliance)也優於我們在近期其他季度所觀察到的水準。本季 GTN 略有改善至 86%,對第二季營收提供了額外支撐。

  • With the anticipated increase in demand for IMCIVREE following FDA approval for acquired HO, product shipments to IMCIVREE Specialties -- to Rhythm Specialty Pharmacy exceeded patient dispenses by approximately $2.9 million, providing a modest benefit to revenue in the quarter. Inventory on hand for specialty pharmacy increased slightly to 20 days as of June 30.

    隨著 FDA 核准後天性 HO 後,IMCIVREE 需求預期增加,我們對 IMCIVREE Specialties(Rhythm 專科藥局)的產品出貨量較病患實際領藥量(dispenses)高出約 290 萬美元,為本季營收帶來小幅助益。截至 6 月 30 日,專科藥局在手庫存天數小幅增加至 20 天。

  • International revenue decreased from $23.2 million to $20.3 million in Q2. Even though we saw a steady increase in the number of patients on reimbursed therapy, the decrease in revenue was mainly attributable to a $3.8 million retrospective charge associated with the French contribution mechanism, which levies the charge on pharmaceutical companies when reimbursed drug sales industrywide exceeds specified statutory thresholds. $2.3 million of this $3.8 million charge was related to 2025 revenue. Excluding this impact, our international business remains strong as evidenced by the continued growth in patients on therapy during the quarter.

    國際營收在第二季由 2,320 萬美元下降至 2,030 萬美元。儘管接受給付治療的病患人數穩定增加,營收下降主要歸因於與法國分攤機制(French contribution mechanism)相關的 380 萬美元追溯性費用(retrospective charge);當全產業的給付藥品銷售額超過法定門檻時,該機制會向製藥公司課徵費用。這 380 萬美元費用中有 230 萬美元與 2025 年營收相關。排除此影響後,我們的國際業務仍維持強勁,從本季治療病患人數持續成長即可見一斑。

  • On slide 27 is a financial snapshot of the second quarter of '26 results compared to the second quarter of 2025. Cost of goods sold this quarter was 12.5% of product revenue within our normal range and primarily driven by cost of materials and royalty payments on setmelanotide in conjunction -- in connection with higher net product revenue during the quarter.

    第 27 張投影片呈現 2026 年第二季業績相較於 2025 年第二季的財務快照。本季銷貨成本占產品營收的 12.5%,落在我們的正常區間內,主要由材料成本以及與 setmelanotide 相關的權利金支付所驅動——並且與本季較高的產品淨營收相呼應。

  • As a percentage of product revenue, COGS varies quarter to quarter based on changes in inventory balances and manufacturing activity, and this quarter increased slightly because of that. R&D expenses were $43.4 million for the second quarter of 2026, compared to $42.3 million in the same period last year.

    以產品營收的百分比來看,銷貨成本(COGS)會因存貨餘額與製造活動的變動而在各季間波動,本季也因此小幅上升。2026 年第二季研發(R&D)費用為 4,340 萬美元,去年同期為 4,230 萬美元。

  • Sequentially, R&D expenses increased $1.7 million compared to the first quarter of 2026. This sequential quarter-over-quarter increase was due to increased spending on bivamelagon clinical trials and preclinical work associated with our congenital hyperinsulinism program. These were partially offset by lower headcount-related costs. The year-over-year increase is primarily attributable to an increase in headcount-related costs, increased costs related to genetic testing and preclinical work, and the increase partially offset by reduced costs associated with RM-718 development and clinical supply.

    就季對季而言,研發費用較 2026 年第一季增加 170 萬美元。此一連續季增主要來自 bivamelagon 臨床試驗支出增加,以及與我們先天性高胰島素血症計畫相關的臨床前工作支出增加。上述增加部分被較低的人力編制相關成本所抵銷。年對年增加主要歸因於人力編制相關成本上升、與基因檢測及臨床前工作相關成本增加;同時,與 RM-718 開發及臨床供應相關成本下降,部分抵銷了增幅。

  • SG&A expenses were $67.4 million for the second quarter of 2026, compared to $45.9 million in the prior period. Sequentially, SG&A expenses increased by $3.8 million or approximately 6% compared to the first quarter of 2026. The increase was primarily driven by higher personnel-related costs to support our expanding commercial operations.

    2026 年第二季銷售、一般及行政(SG&A)費用為 6,740 萬美元,前一期間為 4,590 萬美元。就季對季而言,SG&A 費用較 2026 年第一季增加 380 萬美元,約 6%。此一增加主要由較高的人員相關成本所驅動,以支援我們持續擴張的商業營運。

  • Weighted average common shares outstanding were 68.6 million for Q2 2026. GAAP EPS for the second quarter of 2026 was a net loss per basic and diluted share of $0.73, including $0.02 per share from accrued dividends on convertible preferred stock of $1.1 million.

    2026 年第二季加權平均流通在外普通股為 6,860 萬股。2026 年第二季 GAAP 每股盈餘(EPS)為基本及稀釋後每股淨損 0.73 美元,其中包含可轉換特別股 110 萬美元之應計股利所折算的每股 0.02 美元。

  • Cash used in operations was approximately $9 million during the quarter. We ended the second quarter with approximately $331 million in cash equivalents and short-term investments, which we continue to expect will be sufficient to fund planned operations for at least 24 months.

    本季營運活動使用現金約 900 萬美元。第二季期末我們持有約 3.31 億美元的約當現金及短期投資;我們仍預期該資金足以支應至少 24 個月的既定營運計畫。

  • Lastly, for me on slide 28, there is further detail on our operating expenses for the second quarter and our full-year operating expense guidance. For the second quarter, operating expenses of approximately $110.9 million included $26.1 million of stock-based compensation.

    最後,在第 28 張投影片,我們提供第二季營運費用的更多細節,以及全年營運費用指引。第二季約 1.109 億美元的營運費用中,包含 2,610 萬美元的以股份為基礎之薪酬。

  • Looking ahead to the second half of this year, we are updating our annual OpEx guidance. We now anticipate approximately $363 million to $397 million non-GAAP operating expenses for 2026. Comprised of non-GAAP R&D expenses of $175 million to $195 million, and non-GAAP SG&A expenses of $188 million to $202 million.

    展望今年下半年,我們更新年度營運費用(OpEx)指引。我們目前預期 2026 年非 GAAP 營運費用約為 3.63 億至 3.97 億美元。其中包括非 GAAP 研發費用 1.75 億至 1.95 億美元,以及非 GAAP SG&A 費用 1.88 億至 2.02 億美元。

  • SG&A guidance remains unchanged, while the midpoint of our R&D expense guidance has been reduced by $20 million, as the timing of certain CMC activities related to RM-718 and bivamelagon has shifted from late 2026 to early 2027. We do not expect these changes to affect overall timelines for ongoing or planned clinical development work with either asset.

    SG&A 指引維持不變;而我們研發費用指引的中點下調了 2,000 萬美元,原因是與 RM-718 與 bivamelagon 相關的部分 CMC 活動時程已由 2026 年底延後至 2027 年初。我們不預期這些變動會影響任一資產目前進行中或規劃中的臨床開發工作之整體時程。

  • And with that, I'll turn the call back over to David.

    以上,我把電話交回給 David。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • Thank you, Hunter, and we'll open it up now for Q&A.

    謝謝你,Hunter。接下來我們開放問答(Q&A)。

  • Operator

    Operator

  • (Operator Instructions)

    (接線生指示)

  • Tazeen Ahmad, Bank of America.

    美國銀行(Bank of America)的 Tazeen Ahmad。

  • Tazeen Ahmad - Analyst

    Tazeen Ahmad - Analyst

  • It's early, but can I ask what type of expectations you have around discontinuation rates? Presumably you're not seeing any, but if you are, can you just give us any color on why those might be happening on a go-forward basis? What do you think over time discontinuation from setmelanotide could be for the HO indications. Thanks.

    雖然還很早,但我可以問一下你們對停藥率(discontinuation rates)有什麼樣的預期嗎?推測你們目前應該沒有看到停藥,但如果有的話,能否請你們說明一下未來可能發生的原因?你們認為隨著時間推移,setmelanotide 在 HO 適應症的停藥情況可能會是什麼樣子?謝謝。

  • Jennifer Lee - Executive Vice President, Head of North America

    Jennifer Lee - Executive Vice President, Head of North America

  • Thanks, Tazeen. So it is really early in the launch to articulate color, really, in terms of the discont rate expected. I would say one thing, though. In the past, we have outlined that the global discont rate for the BBS patients was around 30%.

    謝謝你,Tazeen。目前上市初期還非常早,坦白說,要具體說明預期的停藥率還言之過早。不過我可以提一點。過去我們曾說明,BBS 病患的全球停藥率大約在 30% 左右。

  • Holistically, there are differences just in terms of what our data has shown in the BBS patient population versus the HO population in terms of the strength of efficacy that may make that discont rate lower in this particular population.

    整體而言,就我們的數據所顯示,BBS 病患族群與 HO 族群在療效強度上存在差異,這可能使得 HO 族群的停藥率在此特定族群中更低。

  • There is also different factors of the HO population that we're experiencing in terms of the ease of injections and such that may also overall make the ongoing discont rate for this patient population a bit less than the BBS patient population. And that was also seen in the clinical studies, like when you compare the BBS clinical studies versus the HO clinical study and compare the discont rates there.

    此外,我們在 HO 族群也觀察到一些不同因素,例如注射便利性等,整體而言也可能使該族群的持續停藥率略低於 BBS 病患族群。這點在臨床研究中也有呈現,例如比較 BBS 的臨床研究與 HO 的臨床研究時,其停藥率亦可見差異。

  • So it's one thing that we're definitely going to be monitoring. There's a huge focus on as an internal organization. And we'll continue to monitor that moving forward.

    因此,這確實是我們會密切追蹤的一項指標。公司內部對此也高度重視。我們會在未來持續監測。

  • Operator

    Operator

  • Philip Nadeau, TD Cowen.

    TD Cowen 的 Philip Nadeau。

  • Philip Nadeau - Analyst

    Philip Nadeau - Analyst

  • Question on the HO launch seems to be going really well. Based on our math, if you backed out the clinical trial patients. You're doing about 110 patient start forms per month. We're curious to get your thoughts on whether you think that's sustainable for the next couple of quarters. Is there any sign of an early launch bolus or do you expect a more even trajectory to patient starts?

    關於 HO 的上市推進看起來非常順利。依我們的推算,如果把臨床試驗病患扣除,你們每月大約有 110 份病患啟動表(patient start forms)。我們想請教你們是否認為這樣的速度在接下來幾個季度可持續?是否有任何早期上市「一次性湧入」(early launch bolus)的跡象,或你們預期病患啟動會呈現較為平穩的軌跡?

  • Jennifer Lee - Executive Vice President, Head of North America

    Jennifer Lee - Executive Vice President, Head of North America

  • So overall, in terms of the start forms experience in the first quarter, plus the one week since approval, we're really happy in terms of what we're seeing with the RXs coming in. As you mentioned, there's, one-time event in terms of the clinical trial patients. And if you take that out, I would say that in any launch, there may be some patients who were really anxiously waiting in terms of getting that on therapy upon approval.

    整體而言,就第一季加上核准後這一週的啟動表表現來看,我們對目前看到的處方(RXs)進件情況非常滿意。如你所提,臨床試驗病患在數據上屬於一次性事件。若將其排除,我會說任何產品上市時,確實可能有一些病患在核准後非常迫切地想要開始接受治療。

  • With that said, I think all of the launch metrics that we have been really monitor strengthen our belief holistically in terms of this long-term opportunity for sustained ongoing growth in the HO opportunity. As I outlined, the RXs are really coming from a good breadth of prescribers versus being localized in terms of just a few writing the vast majority of these RXs.

    即便如此,我認為我們一直密切追蹤的所有上市指標,都在整體上強化了我們對 HO 長期機會、以及可持續且持續成長的信心。如我先前所述,處方來源涵蓋相當廣泛的開立醫師,而不是集中在少數醫師開出絕大多數處方。

  • We're also seeing a lot of different things around the patients and the background from an age perspective, disease severity, incident versus prevalent patients, which really point to the breadth in terms of patients. Within the HO indication that are really interested in getting onto this therapy. And even with the RXs that we have received, there are still physicians who have additional patients under their care that they have not yet RX. So, overall, a lot of opportunity still remains.

    我們也看到病患在年齡、疾病嚴重程度、新發(incident)與既有(prevalent)病患等背景面向上呈現多樣性,這些都指向病患族群的廣度。在 HO 適應症中,確實有相當廣泛的病患對開始使用此療法很有興趣。此外,即使就我們已收到的處方而言,仍有醫師在其照護下還有其他病患尚未開立處方。因此,整體而言,仍有很多機會存在。

  • I would say that with that said, there are some considerations in terms of the speed of the uptake, which I've said in the past as well. These are really very busy endo offices. They have long wait times for their patients. That can also impact our ability to get in in terms of having the ongoing discussion, but our teams are very persistent from that perspective, but that can take some time just in terms of being able to continue the dialogue with these HCPs.

    不過我也想說,關於導入速度仍有一些需要考量之處,我過去也提過。內分泌科診所真的非常忙碌。病患等候時間很長。這也可能影響我們持續進行討論與推進的能力;但我們的團隊在這方面非常積極且持續投入,只是要能與這些醫療專業人員(HCPs)持續對話,有時仍需要一些時間。

  • The other piece is that all these patients are not yet diagnosed. So it takes some time after we're in there to educate the physician for that patient to come in and be educated and further evaluated by the HCP before they can have that IMCIVREE discussion. And it's a new drug on the market. So some of the physicians, even with more than one patient, they want to experience IMCIVREE before prescribing to all of their patients at once.

    另一個部分是,這些病患都尚未被診斷。因此,在我們介入之後,還需要一些時間去教育醫師,讓該病患能夠前來接受衛教,並在與醫療照護專業人員(HCP)進一步評估後,才能進行關於 IMCIVREE 的討論。而且這是一款新上市的藥物。所以有些醫師即使有不只一位病患,也希望先累積使用 IMCIVREE 的經驗,再一次性地開立給所有病患。

  • So once again, there's so much opportunity that remains. We feel very confident in terms of the ongoing trajectory, but there are some considerations as well.

    所以再說一次,仍然存在非常多的機會。我們對於持續的發展軌跡非常有信心,但同時也有一些需要考量的因素。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • And Phil, as we don't guide toward the future here, but everything that Jennifer just outlined I think speaks strongly to the fact that. Although there may have been a little bit of pent-up urgency, there was no bolus in this thing. We feel really good about all these metrics and how they speak to the future.

    Phil,雖然我們在這裡不對未來提供指引,但 Jennifer 剛才概述的一切,我認為都強而有力地說明了這一點。即便可能存在一些累積已久的迫切需求,但這件事並沒有出現一次性的「爆量」。我們對所有這些指標以及它們對未來的意涵感到非常樂觀。

  • Operator

    Operator

  • Derek Archila, Wells Fargo.

    Derek Archila,富國銀行(Wells Fargo)。

  • Derek Archila - Analyst

    Derek Archila - Analyst

  • I know you highlighted greater than 400 start forms. Again, I think a 2000 number for identified HO patients. So implying about 20% penetration into that pool in 14 weeks. So I guess, should we be thinking that number of identified patients is materially larger now? Thanks.

    我知道你們強調了超過 400 份起始表單。另外,我記得已識別的 HO 病患數大約是 2,000。所以這表示在 14 週內對該族群的滲透率約 20%。那我想問,我們是否應該認為目前已識別的病患數已經實質上更大了?謝謝。

  • Jennifer Lee - Executive Vice President, Head of North America

    Jennifer Lee - Executive Vice President, Head of North America

  • Yeah. Thanks, Derek. We provided that number back in September, and we have not updated that number. We have been ongoing in terms of, since that time, educating additional physicians within our target list, and we still have ways to go in terms of penetrating the full list. So that number in terms of both that suspected or diagnosed HO patient population is. Continue to go.

    是的。謝謝你,Derek。我們在 9 月提供過那個數字,而我們尚未更新該數字。自那之後,我們持續在我們的目標名單中教育更多醫師,而且在滲透完整名單方面仍有進一步空間。因此,無論是疑似或已診斷的 HO 病患族群規模,仍在持續增加。

  • Operator

    Operator

  • Paul Matteis, Stifel.

    Paul Matteis,Stifel。

  • Paul Matteis - Equity Analyst

    Paul Matteis - Equity Analyst

  • I was wondering if you could comment on what you're seeing as it relates to either concomitant use with GLP-1s or whether there's physicians or many physicians are kind of looking to try a GLP-1 before in IMCIVREE. And then I know it's really early on the payer side, but are you seeing any payers put in a GLP-1 step edit? Thanks so much for accessing HO. Thank you.

    我想請你們評論一下,你們觀察到的情況:不論是與 GLP-1 併用,或是醫師(或不少醫師)是否傾向在使用 IMCIVREE 之前先嘗試 GLP-1。另外我知道在付款方(payer)端還很早期,但你們是否看到有任何付款方設定「GLP-1 先行」的階梯式編輯(step edit)?非常感謝你們讓 HO 病患能夠取得治療。謝謝。

  • Jennifer Lee - Executive Vice President, Head of North America

    Jennifer Lee - Executive Vice President, Head of North America

  • Sure. Let me start with the last one. We are pleased just in terms of the progress that are being made around the HO-specific policies. Of the ones that we have in place, there is no step edit requirement in terms of needing to try a GLP before IMCIVREE, which is also something that we're pleased overall with. It's pretty much aligned with our label in terms of background patients.

    當然。我先從最後一個問題開始。就 HO 專屬給付政策的推進而言,我們對目前取得的進展感到滿意。在我們已經建立的那些政策中,並沒有要求必須先嘗試 GLP 再使用 IMCIVREE 的 step edit 規定,這點我們整體也很高興。這基本上與我們標籤(label)中對於病患背景治療的描述一致。

  • Relating to GLP use in the HO patients, of the ones that have been prescribed IMCIVREE, we are experiencing that, this patient population was one that was seeking treatment. So, about 50% of our IMCIVREE prescribed HO patients had prior or current experience on GLP. But currently, there's about 25% of the patients that are currently still on a GLP. And when I outlined that, it's not known in terms of if it's for diabetes versus for the obesity indication. But about 25% of the patient population is on GLP.

    關於 HO 病患使用 GLP 的情況,在已被處方 IMCIVREE 的病患中,我們的經驗是,這個族群本來就積極尋求治療。因此,大約 50% 被處方 IMCIVREE 的 HO 病患,過去或目前有使用 GLP 的經驗。但目前仍有大約 25% 的病患仍在使用 GLP。而我在提到這點時,尚不清楚其用途是糖尿病治療,或是肥胖適應症。但大約 25% 的病患族群正在使用 GLP。

  • I would say that that is also in a time where IMCIVREE wasn't available. There wasn't a specific treatment to treat their underlying condition.

    我會說,這也發生在 IMCIVREE 尚未可用的那段時間。當時並沒有針對其根本病因的特定治療。

  • So as we move forward, it'll be, available for these patients. And that means through the metrics that I just outlined, 50% of these patients were never on a GLP, but still interested in getting onto IMCIVREE after understanding that there was a treatment available for this specific condition.

    因此,隨著我們往前推進,這將會對這些病患變得可取得。而且這也意味著,從我剛才概述的指標來看,這些病患中有 50% 從未使用過 GLP,但在了解針對此特定疾病已有可用治療後,仍然有意願開始使用 IMCIVREE。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • And Paul, just to add a little bit, if you remember from the clinical trial, we had also about 25% of the patients, 30 out of the 120 in the original cohort, who either had a prior experience or were actively on GLPs in the trial, and they came in, met all the criteria for entry, and then had a virtually identical response to IMCIVREE as the others.

    Paul,我再補充一點,如果你還記得臨床試驗的結果,我們在原始隊列的 120 位受試者中,也有大約 25% 的病患(30 位)在試驗前曾使用過 GLP,或在試驗期間仍在使用 GLP;他們進入試驗、符合所有入組標準後,對 IMCIVREE 的反應幾乎與其他人完全一致。

  • So I think, as Jennifer said, it's really, I think, quite instructive, the extent to which a high percentage of these patients have been on GLPs or continue on GLPs, she said, speaking to the unmet need here, but it's not addressing the unmet need here. They're coming over to IMCIVREE. So yeah, I think that overall experience has been really reinforcing that a precision medicine here is the right way to go for this patient population. Thank you.

    所以我認為,正如 Jennifer 所說,這其實很有啟發性:相當高比例的病患曾使用 GLP 或仍在使用 GLP,這反映了此處存在未被滿足的需求,但 GLP 並沒有解決這個未被滿足的需求。他們正在轉向使用 IMCIVREE。所以是的,我認為整體經驗更進一步強化了:對這個病患族群而言,精準醫療是正確的方向。謝謝。

  • Operator

    Operator

  • Dennis Ding, Jefferies.

    Dennis Ding,Jefferies。

  • Dennis Ding - Analyst

    Dennis Ding - Analyst

  • I have a broader question for David. There's been some investor questions around biotech M&A that came out of the asterisk and personal merger speculation. So I'm curious, given Rhythm is obviously a leader in the rare disease space. And David, you're on the board of several biotech companies. I'm curious, how would you characterize pharma M&A appetite recently? Obviously, without going to specific discussions, but do you have any general comments on what pharma is excited about, but also at the same time, if they think premiums may be getting harder to. Just by giving the broader move in the XBI.

    我有一個較宏觀、想請教 David 的問題。近期投資人對生技併購(M&A)有一些疑問,起因於那個帶星號的事件以及個人合併的市場揣測。所以我很好奇,鑑於 Rhythm 顯然是罕見疾病領域的領導者。而且 David,你也在多家生技公司的董事會任職。我想請問,你會如何描述近期大型藥廠對併購的胃納(意願)?當然不談具體個案,但你是否能就藥廠目前特別感興趣的方向做一些概括性的評論?同時,他們是否也認為要付出併購溢價可能變得更困難?尤其考量到 XBI 的整體走勢。

  • And then, as a quick follow-up, the territory manager split 42 for HO and 10 for BBS. Did that get implemented already, or when will that happen? And do you actually expect an acceleration in HO adds in the second half? Thanks so much.

    另外快速追問一下,區域經理(territory manager)的分工是 HO 42 人、BBS 10 人。這個配置已經實施了嗎?還是什麼時候會發生?你們是否真的預期下半年 HO 新增(adds)會加速?非常感謝。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • Yeah. I think let me take that briefly on the biotech M&A, and this is completely unrelated to Rhythm, as you've heard here. We feel really good about where we are and Rhythm's ability to grow as a company and platform and a product and expanding pipeline here. So we're watching like everybody else I am. I think that was a bit of a surprise coming over the weekend, and we'll see how if anything happens there and how it might shake up.

    是的。我先簡短回應生技併購(M&A)這題,這完全與 Rhythm 無關,正如你在這裡聽到的。我們對自身現況以及 Rhythm 作為一家公司、平台與產品的成長能力,並在此擴展研發管線,感到非常有信心。所以我也跟大家一樣在觀察。我認為週末傳出的消息有點出乎意料,我們會看看是否會有任何進展,以及它可能會如何帶來變化。

  • But I think the larger landscape here, pharma with many acquisitions over the first half of the year just speaks to the way our healthcare ecosystem works. We've got a strong and robust early biotech community that's creating value and we have a pharmaceutical community and some mid-sized caps who are looking everywhere to expand their pipelines. So I expect it to continue. I don't see this having a big dampening effect if it were to go forward, but yeah, it's clearly a noteworthy event here. So with that, turnover to Jennifer.

    但我認為更大的產業格局是:大型藥廠在今年上半年進行了多起收購,這反映了我們醫療保健生態系的運作方式。我們有一個強健且活躍的早期生技社群在創造價值,同時也有製藥公司以及一些中型市值公司在各處尋找機會以擴充其研發管線。所以我預期這種趨勢會持續。即便該事件若真的推進,我也不認為會對整體造成很大的抑制效果,但它顯然是一個值得關注的事件。那麼接下來交給 Jennifer。

  • Jennifer Lee - Executive Vice President, Head of North America

    Jennifer Lee - Executive Vice President, Head of North America

  • Relating to the question around the TM split, so this was already implemented. So we already have split the teams into two. I would say that like one of the guiding factors around this decision-making point was we really feel strongly that there's an opportunity in both BBS and HO. I would say the vast majority of the time then of the 42 territories managers when it was combined under their care was already focused on HO.

    關於TM拆分的問題,這其實已經實施了。所以我們已經把團隊分成兩組。我會說,這個決策的一個重要指導因素是,我們非常堅信在BBS和HO兩個領域都存在機會。我會說,當42位區域經理在合併管理時,絕大多數時間其實已經把重心放在HO上。

  • So we just wanted to make sure that we had the right amount of focus also in terms of unlocking the BBS opportunity and being able to get those patients to a diagnosis and treatment as well.

    所以我們只是想確保,在釋放BBS機會、並且也能讓那些病患獲得診斷與治療方面,我們同樣投入足夠且正確的專注度。

  • Operator

    Operator

  • Michael Ulz, Morgan Stanley.

    Michael Ulz,摩根士丹利。

  • Michael Ulz - Analyst

    Michael Ulz - Analyst

  • Maybe just a question on 718 now that you have your early HO data there and it seems to be trending. In line with your other assets, maybe you can talk about early thoughts on read-through to the PWS data and remind us when that data is coming. Thanks.

    也許就718提個問題:現在你們已經有早期的HO數據,而且看起來呈現某種趨勢。似乎與你們其他資產一致;也許你們可以談談對PWS數據的早期看法(是否可作為讀穿/推論),並提醒我們那份數據何時會出來。謝謝。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • Yeah, thanks, Mike. So yeah, we're really pleased with the 718 data. I think remind everybody, all of you've asked me multiple times between these different assets, which one do we think was most likely to be successful. This was before we had the biva data and I was handicapped this to 718, probably had the higher chance of being successful. And we had the very good data on bivamelagon, so that was great.

    好的,謝謝你,Mike。所以,是的,我們對718的數據非常滿意。我想提醒大家,你們很多人之前在不同資產之間多次問我,我們認為哪一個最有可能成功。那是在我們還沒有biva數據之前,而我當時的判斷是718可能成功機率更高。而我們也拿到了bivamelagon非常好的數據,所以那也很棒。

  • But I think this data validates the original hypothesis, which is 718 was built off of setmelanotide and lots of similarities there with a major difference being one, the weekly formulation, but second and importantly, the greater specificity for MC4R, so we really don't have the hyperpigmentation.

    但我認為這些數據驗證了最初的假設:718是以setmelanotide為基礎開發的,兩者有很多相似之處;主要差異在於第一,它是每週一次的劑型;第二且更重要的是,它對MC4R具有更高的專一性,所以我們基本上沒有色素沉著(hyperpigmentation)。

  • And I'll just -- when you run these clinical trials and you ask them to report, there's been this was a case with bivamelagon, there was a few patients in both of these trials where localized quote-unquote increased pigmentation under intense scrutiny, we've tried to get closer on the bivamelagon side.

    我再補充一下——在進行這些臨床試驗、並要求回報時,像在bivamelagon的情況一樣,這兩個試驗中都有少數病患在高度審視下出現局部、所謂「色素增加」的情況;我們在bivamelagon那邊也嘗試更深入釐清。

  • I don't have quite as much detail on the 718, but to me, I don't hear anything in these reports that suggests, to be honest. That this is necessarily drug-related, or if it is, it just highlights the fact that maybe around a nevus or something, a melanocytic nevus, you might get a little more darkening. But again, it's all been super supportive of the fact that these two drugs don't have anywhere near the same level of pigmentation change.

    我對718沒有那麼多細節,但就我而言,我在這些回報中沒有聽到任何跡象,坦白說,顯示這一定與藥物相關;或者即便相關,也只是凸顯可能在痣之類的部位、例如黑色素細胞痣(melanocytic nevus)周圍,會有一點加深。但同樣地,整體都非常支持一個事實:這兩個藥物的色素變化程度,遠遠沒有到同一個層級。

  • With regards to the PWS, yeah, it's very early, again, as we said, we'll update, so we'll complete enrollment by the end of the year, we'll look for an opportunity to update. We've been asked before, will we wait for the results of that, those Prader-Willi data to make a final decision, which asset will go forward, the answer is no. Meaning that that decision-making is being driven much more around.

    至於PWS,是的,現在還非常早期;如同我們說過的,我們會更新:我們會在年底前完成收案,之後會尋找機會對外更新。之前也有人問過,我們是否會等到那些Prader-Willi數據出來,才做最後決定要推進哪個資產;答案是否定的。也就是說,這個決策更多是由……所驅動。

  • To be honest, some of the CMC issues and timing of availability of these different formulations and drug supply, right? If we do everything with one asset, that will put a little more pressure on its supply if we spread it around. So there's a number of things we'll take into consideration over the next few months, which will get us in a position to make that decision, but we're not waiting in terms of our planning and protocols are being drafted. And we're working to be in a position once we have that information to make that decision, we'll be ready to go.

    坦白說,是一些CMC議題,以及不同劑型與藥品供應可取得時程的問題,對吧?如果我們所有事情都用同一個資產,那會讓它的供應承受更大壓力;如果分散配置,壓力就會小一些。所以接下來幾個月我們會把多項因素納入考量,讓我們能做出那個決定;但我們不會因此停下規劃,我們的計畫與試驗方案(protocol)正在起草中。我們也在努力讓自己處於一個狀態:一旦有了那些資訊就能做決策,並且隨時可以啟動。

  • Operator

    Operator

  • Seamus Fernandez, Guggenheim Securities.

    Seamus Fernandez,Guggenheim Securities。

  • Seamus Fernandez - Equity Analyst

    Seamus Fernandez - Equity Analyst

  • So just to -- on my end, hoping you guys could provide us a little bit more color on developments in Japan and how we're likely to see a rollout of HO emerge in Japan. And the pace at which that could play through just a very different market and would be interesting to get a better understanding of how you see that market evolving as it comes forward.

    我這邊想請你們就日本的進展提供更多細節,以及我們可能會如何看到HO在日本的推出與鋪開。以及這在一個非常不同的市場中,可能以什麼樣的速度推進;很希望能更了解你們如何看待該市場在推進過程中的演變。

  • And then just a second question, David, I think there's still a little bit of confusion on this daily versus weekly discussion as it relates to PWS. Just trying to get a better understanding of where you're likely to come out on that. And if there are critical decisions that need to be made along those lines, or do you feel like there's an opportunity that's robust enough in PWS to actually warrant advancing both bivamelagon and 718 to offer a choice to that patient population? Thanks.

    然後第二個問題,David,我覺得在PWS相關的「每日」對「每週」討論上,仍然有一點混淆。想更清楚了解你們最終可能會怎麼定調。以及是否需要在這方面做出關鍵決策;或者你們認為PWS的機會足夠強勁,值得同時推進bivamelagon與718,讓那個病患族群有選擇?謝謝。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • Yeah. Let me just quickly on Japan, and then I'll let Yann make a comment. So we, as Yann indicated, we'll update, we'll do a deeper dive on the Japan opportunity on our next earnings call. He laid out the timeline in terms of what the process we're going through in terms of regulatory review and then we get into pricing negotiations, all of which we expect to put us in a position to launch by the end of the year. But Yann, I don't know if there's any additional color you want to add to your comments.

    好的。我先很快談一下日本,然後我讓Yann補充。如同Yann所提到的,我們會更新,並在下一次財報電話會議上更深入解析日本的機會。他已經說明了我們正在進行的流程時程:先是法規審查,接著進入定價談判;我們預期這些都會讓我們有條件在年底前上市。不過Yann,我不確定你是否還想在你剛才的評論上再補充一些細節。

  • Yann Mazabraud - Executive Vice President, Head of International

    Yann Mazabraud - Executive Vice President, Head of International

  • No, maybe two, three things. Thank you for the question. So first, as you heard, we plan to launch before the end of the year. Two, the prevalence is meaningful. Three, in terms of deficiency in Japan, we can leverage claims data, hospitals data like in the US. We have a strong team in place for many months and a field medical affair teams in place for now six months.

    沒有,或許補充兩三點。謝謝你的提問。第一,如你所聽到的,我們計畫在年底前上市。第二,盛行率相當可觀。第三,就日本的未診斷/診斷不足(deficiency)而言,我們可以像在美國一樣,運用理賠資料、醫院資料。我們已經建立一支強而有力的團隊好幾個月了,且醫學事務的外勤團隊也已到位約六個月。

  • And we also have, which is very important in Japan, the support of the scientific committee, the support of leading experts. And as you may remember, we had a few sites for the HO Phase 3 in Japan, which did help a lot, both in terms of drug understanding adoption and also interaction with the regulators.

    另外,在日本非常重要的一點是,我們也獲得科學委員會的支持,以及領導型專家的支持。而且你可能記得,我們在日本有幾個HO第三期試驗的研究中心,這在兩方面都很有幫助:一是對藥物的理解與採用,二是與主管機關的互動。

  • And maybe the last thing with the regulators and the payers have been myself in Japan a few weeks ago. I've met with some senior executive of the MHLW and what was really clear is that they value a lot, the speed with which Rhythm has tackled the problem, which is an important one for them and the drug lag, drug loss issue, which is, as a meaningful one for Japan, so we are very optimistic in terms of what we can achieve there.

    最後一點,關於主管機關與支付方:我本人幾週前也在日本。我與厚生勞動省(MHLW)的一些高階主管會面;很清楚的一點是,他們非常重視Rhythm處理這個問題的速度——這對他們而言是重要議題——以及所謂藥品延遲(drug lag)、藥品流失(drug loss)問題;這對日本來說也是相當重大的議題,所以我們對於能在那裡達成的成果非常樂觀。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • Great. Thanks. And then with regard to the daily weekly question, I realize this all got triggered, I think, by Dr. Miller's comments on our June conference call where she was strongly in favor of a daily for PWS patients who like their routine. So obviously, we'll take that into consideration as we make final decisions. I'm not sure in the Prader-Willi community, given how complicated this disease is that we'll get one single opinion and we'll obviously get some opinions from some other experts as well.

    很好。謝謝。至於每日與每週的問題,我知道這個討論的起因,我想,是Dr. Miller在我們6月電話會議上的評論;她強烈偏好PWS病患採用每日給藥,因為他們喜歡固定作息。所以很明顯地,我們在做最終決策時會把這點納入考量。我不確定在Prader-Willi社群中,考量到這個疾病的複雜性,我們是否會得到單一一致的意見;我們也會向其他專家徵詢一些看法。

  • So yes, that'll be considered. It's not the overwhelming factor that'll cause us to pick one over the other. And then the last part of your question is, could we envision developing both in Prader-Willi? Absolutely. I think for both HO and Prader-Willi, very significant opportunities, maybe even a comparable magnitude depending on how you cut them. Yeah, we want patients to have that choice. So you can very much imagine that we would get it done, but maybe not in parallel.

    所以,是的,這會被納入考量。但這不會是壓倒性的因素,讓我們因此在兩者之間選擇其一而非另一個。然後你問題的最後一部分是,我們是否能想像在普瑞德-威利症候群(Prader-Willi)中同時開發兩者?當然可以。我認為無論是 HO 還是普瑞德-威利,都有非常重大的機會;依你怎麼切分,規模甚至可能相當。是的,我們希望病患能有那樣的選擇。所以你完全可以想像我們會把它做出來,但也許不會同步並行。

  • Operator

    Operator

  • Jon Wolleben, Citizens.

    Jon Wolleben,Citizens。

  • Jonathan Wolleben - Analyst

    Jonathan Wolleben - Analyst

  • A couple for me. I might have missed this, Jen, but I think last update you said time to prior approval was about 60 to 90 days, and I was wondering if there was an update there. And then can you remind us how many priority accounts you guys have? And with 25% of prescriptions coming from those as of now, do you expect that to accelerate in the near term, or will that take a little bit more time?

    我這邊有幾個問題。Jen,我可能漏聽了,但我記得上次更新你說,從提交到事前核准(prior approval)大約需要 60 到 90 天,我想問現在有沒有更新。另外可以提醒我們,你們有多少個重點帳戶(priority accounts)嗎?以及目前有 25% 的處方來自這些帳戶,你們預期短期內會加速提升嗎,還是還需要一點時間?

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • Sorry, Yann. So the first question was just around the time to approval, 60 to 90 days. What's your sense about where it is now?

    抱歉,Yann。所以第一個問題是關於核准所需時間,60 到 90 天。你覺得現在大概落在哪裡?

  • Yann Mazabraud - Executive Vice President, Head of International

    Yann Mazabraud - Executive Vice President, Head of International

  • Oh, yes, we are expecting the feedback from the --.

    喔,是的,我們正在等待來自-- 的回饋。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • Sorry, Yann. Actually, apologies. That was for Jennifer.

    抱歉,Yann。其實,抱歉。那個是問 Jennifer 的。

  • Yann Mazabraud - Executive Vice President, Head of International

    Yann Mazabraud - Executive Vice President, Head of International

  • Oh, okay, sorry. I have 60, 90 days. I thought it was a surprising (multiple speakers).

    喔,好,抱歉。我聽到的是 60、90 天。我覺得那很令人意外。(多位講者同時發言)

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • No, it's good. I was looking to be updated on the Japan schedule here, but no, it's good. So --.

    不,沒關係。我原本是在看日本時程這邊是否有更新,但沒事,沒關係。所以--。

  • Jennifer Lee - Executive Vice President, Head of North America

    Jennifer Lee - Executive Vice President, Head of North America

  • So from the time to approval standpoint, I would say that holistically on average, we expect that time to approval to continue to get better. I would say that overall, when we take a look at BBS where the payers had very little understanding of diseases impacting the MC4 pathway, little understanding in terms of the differentiation from general obesity. There was a lot of education that we've had to do on the payer side to really educate them on this piece and on IMCIVREE.

    就核准所需時間而言,我會說整體平均來看,我們預期核准時間會持續改善。整體而言,當我們看 BBS 時,付款方對於影響 MC4 路徑的疾病了解非常有限,也不太理解其與一般肥胖之間的差異。因此我們在付款方端做了大量教育工作,讓他們真正理解這一點以及 IMCIVREE。

  • And that helped a lot, even pre-approval as we move forward with the pre-approval discussions with the payers. And that is leading to approvals that are quicker than what we experienced, at least in those early approvals to date than what we experienced with BBS. With that said, we have a lot more pending that we're still working towards.

    這也很有幫助,甚至在核准前,當我們與付款方進行核准前的討論時就已經有所助益。而這正帶來比我們過去經歷更快的核准速度——至少就目前為止的早期核准案例而言——相較於我們在 BBS 上的經驗更快。話雖如此,我們仍有更多待處理案件,還在持續推進中。

  • And we're also working to make sure that we get HO-specific policies in place with the payers as we move forward into the year as well. So that was the question in terms of the time of aprroval. The priority accounts, so these are the accounts that for the most part are where patients with brain tumors go for holistic management of their tumor's pre-surgery and management as well as post-surgery and management in terms of any type of hypothalamic dysfunction.

    我們也在努力確保,隨著今年的推進,能與付款方建立起 HO 專屬的給付政策。所以這就是關於核准時間的問題。至於重點帳戶,這些帳戶多半是腦瘤病患會去的地方,提供腫瘤手術前的整體管理與術後管理,以及任何類型的下視丘功能障礙之管理。

  • So there's around 43 across the nation that our teams have identified and working towards. And it's where, like -- likely the incident, but also the near-term, like, prevalent type of patient population remains for a couple of years after the surgery or procedure to maintain appropriate care. From there, they go on to other sites outside of these centers for treatment.

    全國大約有 43 個,這是我們團隊已辨識並正在推進的。而且像是——可能是新發個案,但也包括短期內的盛行病患族群——在手術或處置後的幾年內仍會留在這些中心,以維持適當照護。之後他們會到這些中心以外的其他院所接受治療。

  • So overall, these are very centralized just in terms of patient populations. And the 25% is aligned with what we have seen in claims to identify patients that may be HO, because within these accounts, we have identified or estimated about 33% of the HO patients are within these centers. So we are going after both physicians within these centers as well as outside, and we're going to continue to make sure that the patients are diagnosed and put on to therapy moving forward.

    所以整體而言,就病患族群來說,這些中心非常集中。而 25% 這個比例與我們從理賠資料(claims)中看到、用來辨識可能為 HO 病患的結果一致;因為在這些帳戶中,我們辨識或估計約有 33% 的 HO 病患位於這些中心。因此我們同時鎖定這些中心內以及中心外的醫師,我們也會持續確保病患能被診斷並在未來接受治療。

  • Operator

    Operator

  • Whitney Ijem, Canaccord.

    Whitney Ijem,Canaccord。

  • Whitney Ijem - Equity Analyst

    Whitney Ijem - Equity Analyst

  • Sorry if I missed this, but you talked about 80% of prescribers being endocrinologists. What are the other 20% and are those doctors that you're proactively targeting or are they just coming to you because they have the patients? Thanks.

    如果我漏聽了先說抱歉,但你提到有 80% 的處方醫師是內分泌科醫師。那另外 20% 是哪些科別?你們是主動鎖定那些醫師,還是他們因為手上有病患而主動找上你們?謝謝。

  • Jennifer Lee - Executive Vice President, Head of North America

    Jennifer Lee - Executive Vice President, Head of North America

  • So the backgrounds of the other 20% are primarily primary care as well as pediatricians. In terms of our target list, we provide the teams also physicians who may have a patient that have backgrounds in terms of potential obesity management holistically, which may include like primary care physicians that are ABOM certified, for example. So the backgrounds in terms of the physicians are endocrinologists, primarily. But also supplemented with these physicians that have interest in obesity medicine overall.

    另外 20% 的背景主要是基層醫療(primary care)以及小兒科醫師。就我們的目標名單而言,我們也會提供團隊一些醫師名單,這些醫師可能有病患,且在整體肥胖管理方面具備相關背景,例如具備 ABOM 認證的基層醫師等。所以醫師背景主要仍是內分泌科。但也會由這些對肥胖醫學整體有興趣的醫師作為補充。

  • Operator

    Operator

  • Samantha Semenkow, Citi.

    Samantha Semenkow,Citi。

  • Samantha Semenkow - Analyst

    Samantha Semenkow - Analyst

  • I just have a follow-up on one that was just asked about 75% scripts that are outside of your priority targets. Can you speak to the type of physician that is writing scripts and how we should think about the growth among that segment going forward? Thanks very much.

    我想追問剛剛那題:有 75% 的處方是在你們重點目標之外。你能談談這些開立處方的醫師類型,以及我們應該如何看待未來該族群的成長嗎?非常感謝。

  • Jennifer Lee - Executive Vice President, Head of North America

    Jennifer Lee - Executive Vice President, Head of North America

  • So outside the priority accounts, the backgrounds are very similar just in terms of the focus in terms of endocrinologists as well as physicians with backgrounds in terms of obesity medicine that have -- we've been tagged as potentially having HO patients for follow up for our teams. We go where the patients lead us to in terms of the target that we have. So there's patients within the priority accounts. There's patients outside of the priority accounts.

    在重點帳戶之外,醫師背景在重點上非常相似,主要仍是內分泌科醫師,以及具備肥胖醫學背景的醫師;我們已將他們標記為可能有 HO 病患,供團隊後續追蹤。就我們的目標而言,病患在哪裡,我們就跟到哪裡。所以重點帳戶內有病患。重點帳戶外也有病患。

  • There's the access issues. So when our teams have a list and they can have an in in terms of being able to engage with the physician, that is where they will go in terms of having the discussion. But we've outlined just in terms of the priority accounts being a key focus because it would enable patients to not leave without diagnosis of HO and would prevent the broader bleed into the community centers moving forward.

    也存在可近性(access)問題。因此當我們的團隊有名單,且能找到切入點去與醫師互動時,他們就會去那裡進行討論。但我們之所以把重點帳戶列為關鍵焦點,是因為這能讓病患在離開前就不會漏掉 HO 的診斷,並可避免未來更大範圍地外溢到社區中心。

  • So we have an ability to really change the paradigm just in terms of how these patient populations are treated, but we go where we can have a discussion with physicians who have the patients.

    所以我們確實有能力改變這些病患族群的治療典範;但我們會去到那些我們能與手上有病患的醫師進行討論的地方。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • And if you think about how our healthcare system works for any complex medical problem, you're perhaps more likely to be seen at an academic center of excellence. You're there, you get your problem managed. And as Jennifer said, these are the chronic management of these patients. They have a lifelong need for pituitary hormone replacement. They will have a lifelong need for management of their hypothalamic obesity.

    而且如果你想想我們的醫療體系在處理任何複雜醫療問題時的運作方式,你可能更有機會先在學術型卓越中心(academic center of excellence)就診。你在那裡把問題處理好。如 Jennifer 所說,這些病患需要長期的慢性管理。他們終身都需要腦下垂體荷爾蒙替代治療。他們也終身都需要對其下視丘性肥胖進行管理。

  • Then they go back to a local endocrinologist, obviously closer to home, somebody they may know better. So as Jennifer said, we'll try to reach all of those patients. Yeah, there's a natural flow here.

    接著他們會回到當地的內分泌科醫師那裡,顯然離家更近,也可能是他們更熟悉的人。所以如 Jennifer 所說,我們會努力觸及所有這些病患。是的,這裡有一個自然的流動。

  • Operator

    Operator

  • Lisa Walter, RBC Capital Markets.

    Lisa Walter,RBC Capital Markets。

  • Lisa Walter - Equity Analyst

    Lisa Walter - Equity Analyst

  • Maybe just another one on RM-718. Given the early but positive results shared today, just curious what are the next steps? Could you perhaps run a basket study across HO and bivamelagon, maybe some of the other indications to accelerate the path to approval and perhaps gain a label eventually similar to him? Any color here would be helpful.

    或許再問一題關於 RM-718。鑑於今天分享的結果雖屬早期但相當正面,我想請教接下來的步驟是什麼?你們是否可能在 HO 與 bivamelagon(以及可能其他一些適應症)上做一個「籃子試驗」(basket study),以加速取得核准的路徑,並最終獲得一個類似於他(him)的標籤?若能提供一些說明會很有幫助。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • Yeah, thanks, Lisa. Yeah, so one, the development path will be at this point indication by indication we've had feedback earlier on, and we'll perhaps go back at some point, I don't think we're there yet, that the regulators, FDA specifically, was not ready to entertain something like an MC4R pathway label, which might argue you have the ability to treat anybody where you can document there's a pathway label. So given that, we'll be going indication by indication, one.

    好的,謝謝,Lisa。是的,首先,目前的開發路徑會是以適應症逐一推進;我們先前已收到一些回饋,之後可能會在某個時間點再回去溝通——我認為我們還沒到那一步——監管機關,特別是 FDA,尚未準備好考慮像 MC4R 路徑標籤(pathway label)這樣的作法;那種作法可能意味著,只要你能證明存在該路徑,就有能力治療任何人。因此,在這樣的前提下,我們會逐一適應症推進,這是第一點。

  • Two, our plan will be for all of our currently approved indications, so the POMC leptin receptor biallelic, the BBS population, we will get one of our two next-generation molecules into those populations and get the indication. We may not develop both molecules in all of those indications even if they're smaller, but as I said in my earlier response, for the large indications, HO and Prader-Willi specifically, we very much may entertain developing both of these molecules.

    第二,我們的計畫是針對目前所有已核准的適應症——也就是 POMC、leptin receptor(瘦素受體)雙等位基因(biallelic)以及 BBS 族群——我們會把兩個次世代分子中的其中一個導入這些族群並取得該適應症。即便某些適應症規模較小,我們也未必會在所有適應症上同時開發兩個分子;但如我先前回覆所說,對於大型適應症,特別是 HO 與 Prader-Willi,我們很可能會考慮同時開發這兩個分子。

  • Operator

    Operator

  • Priyanka Grover, JPMorgan.

    Priyanka Grover,JPMorgan。

  • Priyanka Grover - Analyst

    Priyanka Grover - Analyst

  • Hi, guys. Thanks so much for taking our question, and congrats on the quarter. So we just have a question about Europe. Aside from the one-time revenue recognition charge in France, were there any other factors to think about for Europe? In the past quarters, Europe has been a strong growth driver for Rhythm. I'm so curious how are you thinking about Europe going forward, especially with acquired HO launch in 2027? Thanks.

    嗨,各位。非常感謝讓我們提問,也恭喜本季表現。我們想問一個關於歐洲的問題。除了法國一次性的收入認列調整(charge)之外,歐洲還有其他需要考量的因素嗎?在過去幾季,歐洲一直是 Rhythm 強勁的成長動能來源。我很好奇你們對歐洲未來的看法,尤其是 2027 年取得 HO 上市(launch)之後?謝謝。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • Yann?

    Yann?

  • Yann Mazabraud - Executive Vice President, Head of International

    Yann Mazabraud - Executive Vice President, Head of International

  • Yes, thank you for the question. So maybe a few words about the HO launch in 2027. First, we are encouraged by what we are seeing in France and Italy in terms of diagnosis and willingness to treat. As we have named-patient cells in place for more than one year in those two countries. So we have observed the conviction, the growing conviction among the treating community.

    是的,謝謝你的提問。那我先談幾點關於 2027 年 HO 上市。首先,從診斷以及治療意願的角度來看,我們對目前在法國與義大利看到的情況感到鼓舞。因為我們在這兩個國家已建立「名義病人」(named-patient)機制超過一年。因此我們觀察到治療社群的信心,以及持續增強的信心。

  • Another very positive aspect is that we will leverage most, if not all, the same centers of excellence and prescribers that we already have for PPL and BBS, but we also have new medical specialties to explore, as Jennifer also mentioned in the US. So we feel good.

    另一個非常正面的面向是,我們將能運用大部分——如果不是全部——我們目前在 PPL 與 BBS 已合作的相同卓越中心(centers of excellence)與處方醫師;但同時我們也有新的醫療專科可去開拓,正如 Jennifer 也在美國提到的。所以我們感覺良好。

  • We also know very well the payers because we have spoken with them for many years, and these are the same teams across Europe. And they know the drug very well and they know the drug benefits very well. So with all that and other aspects, we feel good.

    我們也非常了解付款方(payers),因為多年來我們一直與他們溝通,而在歐洲各地也都是同一批團隊。他們非常了解這個藥,也非常了解藥物帶來的效益。因此,綜合這些以及其他因素,我們感覺良好。

  • Operator

    Operator

  • Thomas Smith, Leerink Partners.

    Thomas Smith,Leerink Partners。

  • Thomas Smith - Analyst

    Thomas Smith - Analyst

  • Hey, good morning. Sorry about that. Thanks for taking our questions. And let me add my congrats on the strong quarter and RM-718 data here. Just on 718, wondering if you could expand a little bit on the comments regarding the dose escalation in the study, how many of these initial HO patients are getting up to the target dose?

    嗨,早安。抱歉剛剛那樣。謝謝讓我們提問。也讓我補一句,恭喜本季表現強勁以及 RM-718 的數據。關於 718,我想請你們再多談一點試驗中的劑量遞增(dose escalation)相關評論:這些最初的 HO 病人中,有多少人已經加到目標劑量?

  • And then just on the tolerability profile, could you provide a little bit more color on the injection site reactions and how those compare to the IMCIVREE experience? Thanks so much.

    另外關於耐受性(tolerability)特徵,你們能否再多說一些注射部位反應(injection site reactions),以及它們與 IMCIVREE 的經驗相比如何?非常感謝。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • Sure. So the vast majority got to the 40 milligrams, as they indicated. We had one patient who actually didn't get much above 10 or 20 mgs. They might have reached 20 mgs weekly but were having nausea. And we saw this in our earlier development program with setmelanotide, where there was a small percentage of patients who just were extraordinarily sensitive in terms of their GI side effects, and I think that's part of the background of this disease. But aside from that, everybody basically got to the 40 mgs.

    當然。如同他們所說,絕大多數都加到了 40 毫克。我們有一位病人實際上沒有加到超過 10 或 20 毫克太多。他們可能每週加到 20 毫克,但出現噁心。我們在先前 setmelanotide 的早期開發計畫中也看過這種情況:有一小部分病人在腸胃道(GI)副作用方面特別敏感;我認為這也是此疾病背景的一部分。但除此之外,基本上每個人都加到了 40 毫克。

  • The injection-site reactions, its reactions slash the way the drug works. This is a weekly formulation. The formulation itself is somewhat viscous and they -- mechanism, essentially, you inject and you get a nodule in the subcutaneous tissue under the skin, and then the drug disperses from there. So that's how it's delivered. The nodule is present, and I think in the case of, the patient who wasn't thrilled with the injections, part of it was, didn't like the nodules per se.

    注射部位反應,某種程度上是反應/也是藥物作用方式的一部分。這是一個每週一次的劑型。該配方本身有些黏稠,而其機制基本上是:注射後會在皮下組織形成一個結節(nodule),然後藥物從那裡逐步擴散。所以它就是這樣被遞送的。結節會存在;我想就那位對注射不太滿意的病人而言,其中一部分原因是他本身不喜歡這些結節。

  • And the other thing is we're also -- we're delivering this drug without. The autoinjector and so it has to be pushed in by hand and the autoinjector we know for a fact will make a significant difference I think in terms of the ease and also probably the patient experience. But that's what for the most part is being referenced when they reported the injection site reaction, the formation of this nodule which is just part of how the drug is delivered.

    另外一點是,我們目前也是在沒有使用自動注射器(autoinjector)的情況下給藥。因此必須手動推注;而我們確知自動注射器在便利性、以及可能的病人使用體驗方面,會帶來顯著差異。但他們所回報的注射部位反應,多數指的就是這個結節的形成——這只是藥物遞送方式的一部分。

  • Operator

    Operator

  • Joseph Stringer, Needham & Company.

    Joseph Stringer,Needham & Company。

  • Joseph Stringer - Analyst

    Joseph Stringer - Analyst

  • Hi, good morning. Thank you so much for taking our questions. Question on the early-stage pipeline. You have a CHI program in preclinical development. Can you provide any updates there? And more broadly, any updated thoughts on pipeline expansion beyond the MC4R assets?

    嗨,早安。非常感謝讓我們提問。我想問早期管線(early-stage pipeline)。你們有一個 CHI 計畫正處於臨床前開發。能否提供任何最新進展?更廣泛地說,對於在 MC4R 資產之外擴充管線,你們是否有更新的想法?

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • Yeah, thanks, Joe. So CHI, we've been working on it for a while here, as and we look forward to updating you. As I've said before, and I'll say it again, we're actually making good progress there. We look forward to an update. We're not prepared to give one today, but we are making good progress. And as Hunter highlighted, we're beginning to increase our spend there. So we're moving deeper into the developmental program.

    好的,謝謝,Joe。關於 CHI,我們已經投入一段時間在做了;我們也期待向各位更新。如我之前說過、我再說一次,我們在那方面其實進展良好。我們期待提供更新。今天我們還沒準備好對外說明,但我們確實取得了良好進展。而且如 Hunter 所強調的,我們也開始增加在那方面的支出。所以我們正在更深入推進開發計畫。

  • So we'll talk more about that. We're excited about that program. I think we have a unique approach to addressing that disease, but more to come there.

    因此我們之後會再多談一些。我們對這個計畫感到興奮。我認為我們在處理該疾病上有一個獨特的方法,後續還會有更多內容。

  • I think in terms of other approaches here, we'll continue to think about the biology around the MC4R pathway, signaling through the receptor. And the like every company, we entertain other approaches to these diseases and we're doing some of that. We're not at the point now where we're in a position to talk about that, but we'll look at that.

    至於其他方法,我們會持續思考 MC4R 路徑周邊的生物學,包括透過受體的訊號傳導等。而且像所有公司一樣,我們也會評估針對這些疾病的其他策略,我們也正在做其中一些工作。目前我們還沒到可以對外談論的階段,但我們會持續評估。

  • And then externally, we got this question, would you consider going outside? And I think our answer continues to be, we feel really good about the opportunities in front of us, the pipeline and the product strategy we've been pursuing and there's many indications, including our whole genetic pillar, if you will, which we will absolutely come back to and work our way through there.

    然後在外部方面,我們收到這個問題:你們會考慮走向外部嗎?我想我們的回答仍然是:我們對眼前的機會、我們一直在推進的研發管線與產品策略感到非常有信心,而且有許多跡象——包括我們整個遺傳學支柱(如果你願意這麼稱呼)——我們絕對會再回來,並在那部分逐步深入推進。

  • And as we look at some things, biomarkers, for example, we're continuing to try to understand how we can better understand and refine the patient population most likely to respond in terms of that genetic population. So that's going to be our focus.

    當我們檢視一些事項時,例如生物標誌物,我們持續嘗試理解:如何能更好地了解並精煉最可能有反應的病患族群,特別是在那個遺傳族群的層面。所以那將會是我們的重點。

  • That said, we'll remain opportunistic. We're obviously in a stronger position in terms of our balance sheet and our position as a company. So we'd be, not averse to doing something that made sense, but we're not specifically looking to do something, so.

    話雖如此,我們也會保持機會主義。顯然,就資產負債表以及公司整體處境而言,我們現在處於更強的位置。因此,如果有合理且有意義的事情,我們不會排斥去做,但我們並沒有特別在尋找要做什麼,所以。

  • Operator

    Operator

  • Ram Selvaraju, HC Wainwright.

    Ram Selvaraju,HC Wainwright。

  • Raghuram Selvaraju - Analyst

    Raghuram Selvaraju - Analyst

  • Thanks so much for taking our question. Just with respect to Prader-Willi syndrome, given the extended history so far with at least one approved drug in that condition and greater familiarity overall with that target indication. Can you share with us any additional information at this time regarding market segmentation analysis, and what you anticipate to be the key patient population within the Prader-Willi syndrome community that you might focus on for your product? Thank you.

    非常感謝讓我們提問。就普瑞德-威利症候群(Prader-Willi syndrome)而言,鑑於目前為止在該適應症上已有至少一款獲批藥物的較長歷史,且整體上對該目標適應症也更為熟悉。你們能否在此時分享更多關於市場區隔分析的資訊,以及你們預期在普瑞德-威利症候群社群中,對於你們產品而言可能會聚焦的關鍵病患族群是哪些?謝謝。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • Yeah, thanks. I think, so one, as we've indicated on our prior calls, our initial developmental indication as other companies in the space have done following the [selenol] approval would be for hyperphagia. It makes total sense. There's a very clear, I think, template for how that trial can and should be done.

    好的,謝謝。我想,第一,正如我們在先前的電話會議中所指出的,在[selenol]獲批之後,與該領域其他公司所採取的做法一致,我們最初的開發適應症會是針對暴食(hyperphagia)。這完全合理。我認為在試驗如何以及應該如何進行方面,有一個非常清楚的範本。

  • Our mechanism, as we said, we started with a very clear focus on both hunger/hyperphagia and BMI weight change because our drug signaling through this receptor gives you a satiety signal, increases energy expenditure. And we always believe that we got a weight change, BMI decrease, we would of course achieve that end by in some way decreasing caloric intake, decreasing hunger/hyperphagia.

    就我們的作用機制而言,如同我們所說,我們一開始就非常明確地聚焦在飢餓/暴食以及BMI體重變化,因為我們的藥物透過這個受體傳遞訊號,會給予飽足訊號並提高能量消耗。而我們一直相信,如果我們能看到體重變化、BMI下降,當然也會在某種程度上透過降低熱量攝取、降低飢餓/暴食來達成這個結果。

  • So long story short is we'll continue to pursue that paradigm. I think in terms of market segmentation -- no, I think it's way too early. I think this is an extremely complex disease. You all know it as well as we do or maybe better, some of you. It's remarkably heterogeneous, but they share a lot of common features.

    簡而言之,我們會持續推進這個範式。至於市場區隔——不,我認為現在談還太早。我認為這是一種極其複雜的疾病。你們對它的了解跟我們一樣,甚至有些人可能比我們更了解。它的異質性非常高,但也共享許多共同特徵。

  • Currently approved therapies have some limitations. We know that. I don't think there's likely to be one drug solution to Prader-Willi. So obviously, we've included patients who are on VYKAT in our current trial that Dr. Miller's running. So combination therapy is another strategy that I'm sure the community looking at. And we'll be thinking about as we get, go through our developmental plans and the like.

    目前已獲批的治療有一些限制。我們知道這點。我不認為普瑞德-威利會有單一藥物就能解決的方案。因此,很明顯地,我們在目前由Miller醫師主持的試驗中,已納入正在使用VYKAT的病患。所以合併療法是另一個策略,我相信社群也在關注。而我們在推進開發計畫等工作時,也會一併思考。

  • But no, I think our goal is to serve the Prader-Willi population writ large, recognizing that the clinical trials might need to be more targeted to run that successful trial.

    但不,我想我們的目標是服務整體普瑞德-威利族群,同時也認知到,臨床試驗可能需要更聚焦,才能成功完成該試驗。

  • Operator

    Operator

  • Thank you. Thank you. This concludes our question-and-answer session. I'd like to turn it back to David Meeker for closing remarks.

    謝謝。謝謝。我們的問答環節到此結束。我想把時間交回給David Meeker做結語。

  • David Meeker - Chairman, President, and Chief Executive Officer

    David Meeker - Chairman, President, and Chief Executive Officer

  • Great. Well, thanks everybody for tuning in August. As you've heard, incredibly excited, I'll say, about our start here. I mean, we've been working on HO for a number of years, and now to be at a point where we're actually getting the drug to patients and we're seeing a community that's embracing it and responding well to their initial experiences, like I said, it's very exciting for us. Lots more to come. And hopefully, we've outlined some of that. We'll have more discussions going forward, but we look forward to our next update on the Q3 call.

    很好。感謝各位在八月收聽。如各位所聽到的,我可以說,我們對於目前的起步感到無比興奮。我的意思是,我們在HO上已經投入多年,而現在能走到真正把藥物提供給病患、並看到社群正在接納它,且對初期使用經驗反應良好——如我所說,這對我們而言非常令人振奮。後續還有很多進展。也希望我們已經概述了其中一些。未來我們會有更多討論,但我們也期待在第三季(Q3)電話會議上提供下一次更新。

  • Operator

    Operator

  • This concludes today's conference call. Thank you for participating, and you may now disconnect.

    今天的電話會議到此結束。感謝各位參與,現在您可以掛線。